title: Malignant (Diffuse) Mesothelioma in Patients With Hematologic Malignancies: A Clinicopathologic Study of 45 Cases.
abstract: BACKGROUND
  Ionizing radiation has a role in the development of malignant mesothelioma, in several epidemiologic studies, including patients with hematologic malignancies.
  
  
  OBJECTIVE
  To study the clinicopathologic characteristics of patients with malignant mesothelioma and hematologic malignancies with and without a history of radiotherapy.
  
  
  METHODS
  From a database of approximately 3600 patients with malignant mesothelioma, we identified 45 patients (1%) who also had hematologic malignancies. We examined clinicopathologic features and noted whether the patient had received radiotherapy for malignancy, comparing those with and those without such exposure.
  
  
  RESULTS
  Among the 45 cases, 18 (40%) had Hodgkin lymphoma, 15 (33%) had non-Hodgkin lymphoma, 10 (4%) had chronic lymphocytic leukemia, and 2 (22%) had chronic myelogenous leukemia; 20 patients (44%) had a history of radiotherapy, and 23 (51%) did not. Most patients with Hodgkin lymphoma (16 of 18; 90.0%) received radiation, whereas none of the patients with leukemia (0 of 12) and only 20% (3 of 15) of the patients with non-Hodgkin lymphoma did so. Patients without radiation were older than patients who received radiotherapy (median, 73 versus 54 years, respectively; P < .001), had a shorter interval from diagnosis of hematologic malignancy to that of mesothelioma (median, 2 versus 24 years, respectively; P < .001), and had a shorter survival period (median, 6.0 versus 14.0 months, respectively; P = .02). Epithelial mesotheliomas were proportionately more common in patients with a history of radiotherapy.
  
  
  CONCLUSIONS
  Patients with mesothelioma and hematologic malignancies with a history of radiation tended to be younger, had a longer interval from diagnosis of hematologic malignancy to that of mesothelioma, had a longer survival period, and were more likely to have the epithelial variant compared with patients without radiotherapy.
authors.forename: Xin
authors.initials: X
authors.lastname: Li
authors.forename: Noel A
authors.initials: NA
authors.lastname: Brownlee
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Sporn
authors.forename: Annabelle
authors.initials: A
authors.lastname: Mahar
authors.affiliation: From the Department of Pathology, Duke University Medical Center, Durham, North Carolina (Drs Roggli and Sporn); the Department of Pathology, Tianjin Haihe Hospital, Tianjin Institute of Respiratory Diseases, Tianjin, China (Dr Li); the Pathology Associates of Greenville, Greenville, South Carolina (Dr Brownlee); and the Department of Anatomical Pathology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia (Dr Mahar).
authors.forename: Victor L
authors.initials: VL
authors.lastname: Roggli
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001194:Asbestos / Q000009:adverse effects; D002648:Child; D005260:Female; D019337:Hematologic Neoplasms / Q000473:pathology* / Q000532:radiotherapy; D006689:Hodgkin Disease / Q000473:pathology; D006801:Humans; D053208:Kaplan-Meier Estimate; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000473:pathology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology; D008175:Lung Neoplasms / Q000209:etiology / Q000401:mortality / Q000473:pathology*; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology; D008297:Male; D008654:Mesothelioma / Q000209:etiology / Q000401:mortality / Q000473:pathology*; D000086002:Mesothelioma, Malignant; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary / Q000209:etiology / Q000473:pathology*; D009381:Neoplasms, Radiation-Induced / Q000209:etiology / Q000473:pathology; D011878:Radiotherapy / Q000009:adverse effects; D012307:Risk Factors; D013997:Time Factors; D055815:Young Adult
chemical_list: D001194:Asbestos